C

    Compass Pathways Plc (CMPS)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $13.51
    -0.22 (-1.60%)

    Market Cap: $1.90B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(16/25)
    Avg Surprise
    +3.03%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.33
    Range$-0.41 - $-0.25
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.34-4.5%
    60d ago$-0.34-4.5%
    30d ago$-0.31+5.1%
    7d ago$-0.35-6.1%
    Current$-0.33
    Revenue Consensus
    $0
    Range$0 - $0
    14 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.45
    Range$-1.30 - $-0.09
    5 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.45---
    Sep 26EST
    		-$-0.33---
    Jun 26
    Reported Jul 30
    		$-0.36$-0.46+21.74%Beat+12.2%
    Mar 26
    Reported May 13
    		$-0.30$-0.31+3.23%Beat+28.6%
    Dec 25
    Reported Mar 24
    		$-0.61$-0.40-52.66%Miss+3.7%
    Sep 25
    Reported Nov 4
    		$-0.38$-0.40+5.00%Beat+32.1%
    Jun 25
    Reported Jul 31
    		$-0.41$-0.37-10.81%Miss+26.8%
    Mar 25
    Reported May 8
    		$-0.42$-0.49+14.29%Beat+23.6%
    Dec 24
    Reported Feb 27
    		$-0.63$-0.63+0.00%Beat-18.9%
    Sep 24
    Reported Oct 31
    		$-0.56$-0.59+5.08%Beat+16.4%
    Jun 24
    Reported Aug 1
    		$-0.56$-0.55-1.82%Miss+9.7%
    Mar 24
    Reported May 8
    		$-0.55$-0.49-12.24%Miss+3.5%
    Dec 23
    Reported Feb 29
    		$-0.53$-0.34-55.88%Miss+27.4%
    Sep 23
    Reported Nov 2
    		$-0.67$-0.42-59.52%Miss-55.8%
    Jun 23
    Reported Aug 3
    		$-0.62$-0.70+11.43%Beat-24.0%
    Mar 23
    Reported May 11
    		$-0.57$-0.65+12.31%Beat-14.0%
    Dec 22
    Reported Feb 28
    		$-0.73$-0.59-23.73%Miss-19.7%
    Sep 22
    Reported Nov 3
    		$-0.43$-0.64+32.81%Beat-13.2%
    Jun 22
    Reported Aug 4
    		$-0.50$-0.60+16.67%Beat-13.6%
    Mar 22
    Reported May 10
    		$-0.50$-0.67+25.37%Beat-42.9%
    Dec 21
    Reported Feb 24
    		$-0.61$-0.50-22.00%Miss-17.3%
    Sep 21
    Reported Nov 9
    		$-0.38$-0.47+19.15%Beat+17.4%
    Jun 21
    Reported Aug 11
    		$-0.44$-0.37-18.92%Miss-131.6%
    Mar 21
    Reported May 13
    		$-0.35$-0.47+25.53%Beat+0.4%
    Dec 20
    Reported Mar 9
    		$-0.52N/A+62.59%Beat-98.9%
    Sep 20
    Reported Nov 12
    		$-0.46$-0.68+32.35%Beat-2.1%
    Jun 20
    Reported Sep 21
    		$-0.19$-0.35+45.71%Beat+60.4%
    Dec 19
    Reported Dec 31
    		$-0.35N/AN/ABeat-
    Sep 19
    Reported Sep 30
    		$-0.26N/AN/ABeat-
    Jun 19
    Reported Jun 30
    		$-0.45N/AN/ABeat-
    Mar 19
    Reported Mar 31
    		$-0.48N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-8.21EV/EBITDA-3.51x
    Price/FCF-7.85xFCF Yield-12.74%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-319.10%ROIC-128.08%
    Financial Health
    Debt/Equity0.62xInterest Coverage-34.13x
    Current Ratio1.30xQuick Ratio1.30x
    Trading Statistics
    Beta2.53Avg Volume2.69M
    52-Week High$15.4052-Week Low$4.55

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.06
    SMA 20$13.72
    SMA 50$13.09
    SMA 200$9.01
    EMA 10$13.94
    EMA 20$13.63
    EMA 50$12.89
    EMA 200$9.77

    MACD

    Line: 0.42Signal: 0.44Hist: -0.02

    ADX

    ADX: 24.4+DI: 25.1-DI: 21.3

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down4.0
    PSAR$15.01

    Bollinger Bands

    Upper Band$15.03
    Lower Band$12.40
    %B Position1918%(Upper)
    Band Width0.42

    RSI (14-Day)

    Neutral
    50.6

    Momentum Oscillators

    Stoch %K46.2
    Stoch %D65.7
    Williams %R-76.9
    ROC (10d)-1.5%
    Momentum-0.21
    CCI (20d)-9.5
    MFI (14d)57.8

    Volatility Measures

    ATR (14d)$0.75(5.5%)
    StdDev (20d)0.66
    Hist Vol77.6%(High)

    Volume Flow

    VWAP$13.63
    OBV104.1M
    AD Line-21.2M
    CMF (20d)0.139

    Volume Metrics

    Avg Vol (20d)2.7M
    Vol Ratio0.7x
    VWMA (20d)$13.71

    Pivot Points

    R3$15.42
    R2$15.06
    R1$14.40
    Pivot Point$14.04
    S1$13.38
    S2$13.02
    S3$12.35

    Advanced Oscillators

    TSI14.30
    Ultimate Osc46.6
    KST128.24

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$3.68M$0
    Cost of RevenueN/AN/A$5,991$14,909$159,869N/AN/AN/A$63,070$60,965$1.84M$658,158
    Gross ProfitN/AN/A$-5,991$-14,909$-159,869N/AN/AN/A$-63,070$-60,965$1.84M$-658,158
    Operating Expenses$52.37M$42.90M$45.95M$40.54M$42.93M$49.62M$48.41M$47.90M$43.32M$38.57M$38.41M$34.06M
    R&D$29.18M$26.48M$29.91M$23.40M$30.32M$30.88M$32.14M$32.93M$29.07M$24.90M$27.14M$21.53M
    SG&A$23.20M$16.42M$16.05M$13.21M$12.61M$18.74M$16.27M$14.97M$14.25M$13.67M$11.27M$12.54M
    Operating Income$-52,372,000$-42,904,000$-45,952,000$-40,536,000$-42,933,000$-49,616,000$-48,414,000$-47,896,000$-43,322,000$-38,573,000$-38,405,000$-34,062,000
    Interest Income$3.74M$2.42M$1.31M$1.59M$1.90M$2.39M$1.62M$1.98M$2.41M$2.26M$0$0
    Interest Expense$1.48M$1.46M$1.14M$1.10M$1.15M$1.12M$1.13M$1.14M$1.11M$1.10M$1.12M$1.08M
    Income Before Tax$-253,463,000$91.19M$-96,612,000$-137,947,000$-38,266,000$-17,510,000$-42,309,000$-38,329,000$-37,925,000$-34,965,000$-32,138,000$-33,327,000
    Income Tax Expense$331,000$-11,000$-2,734,000$-230,000$137,000$354,000$1.02M$173,000$176,000$222,000$394,000$62,000
    Net Income$-253,794,000$91.20M$-93,878,000$-137,717,000$-38,403,000$-17,864,000$-43,332,000$-38,502,000$-38,101,000$-35,187,000$-32,532,000$-33,389,000
    EBITDA$-251,980,000$92.66M$-95,469,000$-136,833,637$-36,957,000$-16,349,000$-41,127,000$-37,133,000$-36,750,000$-33,806,000$-31,014,000$-32,061,000
    EBITN/A$92.60M$-95,475,000$-136,848,637$-37,115,000$-16,386,000$-41,177,000$-37,192,000$-36,813,000$-33,867,000$-30,912,000$-32,247,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CMPS

    News

    Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026

    COMPASS Pathways Plc (Nasdaq: CMPS) announced its participation in the 2026 Cantor Global Healthcare Conference on September 9, 2026. Management will participate in a fireside chat and a panel discussion titled "PSYCH! Accessing The New Wave of Psychedelics." A live audio webcast will be available on the company's investor relations website.

    Investing News Network•9/1/26•
    Somewhat-Bullish

    Compass Pathways: Still A Buy, But The Exit Just Got Complicated (NASDAQ:CMPS)

    COMPASS Pathways (CMPS) remains a "Buy" due to its psychedelic drug COMP360 for treatment-resistant depression, targeting H1 2027 approval. However, Eli Lilly's acquisition of AtaiBeckley and the competitive threat from BPL-003, which offers shorter treatment sessions, complicate CMPS's long-term strategy and market position. While CMPS has sufficient cash until 2028, commercialization may necessitate further capital, risking dilution or debt.

    Seeking Alpha•8/25/26•
    Neutral

    How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions

    COMPASS Pathways is collaborating with the U.S. Department of Veterans Affairs on the PIVOT trial, testing its COMP360 psilocybin for veterans with treatment-resistant depression and PTSD. This partnership broadens the potential clinical evidence for psilocybin-assisted therapy in complex mental health conditions, though the company's primary focus remains on the NDA submission process for COMP360. The trial may influence COMPASS Pathways' investment narrative and long-term outlook, but investors should also consider financial risks and varying analyst revenue forecasts.

    Sahm•8/21/26•
    Somewhat-Bullish

    How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions

    COMPASS Pathways has partnered with the U.S. Department of Veterans Affairs on the PIVOT trial to test its COMP360 psilocybin in veterans with treatment-resistant depression and concurrent PTSD. This collaboration expands the potential clinical evidence for psilocybin-assisted therapy in complex mental health conditions. While significant, the trial complements COMPASS Pathways' ongoing NDA process for COMP360 in treatment-resistant depression, which remains the primary short-term catalyst, with investors also needing to consider financing and dilution risks.

    Simply Wall Street•8/20/26•
    Somewhat-Bullish

    Compass Pathways (NASDAQ:CMPS) Raised to "Sell" at Wall Street Zen

    Wall Street Zen has downgraded Compass Pathways (CMPS) from "strong sell" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with a $23.36 target price. The company's shares opened at $13.45, reflecting a 1.2% increase, and it recently reported a quarterly loss of $1.88 per share, significantly missing analyst estimates. Institutional investors currently hold 46.19% of the stock.

    MarketBeat•8/16/26•
    Somewhat-Bearish

    Frequently Asked Questions About CMPS

    Does CMPS pay dividends?
    Compass Pathways Plc (CMPS) does not currently pay a regular dividend.
    What is CMPS's market cap?
    Compass Pathways Plc (CMPS) has a market capitalization of $1.90B with a current stock price of $13.51.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In